Consistent with the idea that the ERK5 pathway is stimulated downstream of HER2–HER3 complexes (24), trastuzumab, which acts by selectively blocking HER2 dimers (51), did not inhibit ERK5 hyperphosphorylation in BT474 breast cancer cells (Fig. 6C). Here, ERBB3 is linked to breast cancer.